Diagnosis and treatment of sarcoma of the uterus. A review

References

• World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Tavassoli FA, Devilee P, editors. Lyon: IARC Press; 2003.
   Google Scholar
• McCluggage WG. Malignant biphasic uterine tumours: Carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002;55:321–5.
   PubMed Web of Science ®Google Scholar
• D’Angelo E, Prat J. Uterine sarcomas: A review. Gynecol Oncol 2010;116:131–9.
   PubMed Web of Science ®Google Scholar
• Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases. Int J Cancer 2006;119:2922–30.
   PubMed Web of Science ®Google Scholar
• SINTEF. Primary treatment of ovarian cancer. SMM report 5/2003. Oslo, Norway: Norwegian Centre for Health Technology Assessment; 2003.
   Google Scholar
• Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334–6.
   PubMed Web of Science ®Google Scholar
• Liddle J, Williamson M, Irwig L. Method for evaluating research and guideline evidence (MERGE). Sydney, Australia: New South Wales Department of Health; 1996.
   Google Scholar
• Scottish Intercollegiate Guidelines Network: SIGN 50: A guideline developers’ handbook. Edinburgh, Scotland: SIGN; 2001, 2004.
   Google Scholar
• Casali P, Licitra L, Tondini C, de Braud F, Bruzzi P, Costa A, . START: A European state-of-the-art on-line instrument for clinical oncologists. Ann Oncol 1999;10:769–73.
   PubMed Web of Science ®Google Scholar
• Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001;40:340–60.
   PubMed Web of Science ®Google Scholar
• Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54:355–64.
   PubMed Web of Science ®Google Scholar
• Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956–1992: Incidence, survival and mortality. Eur J Cancer 1997;33:907–11.
   PubMed Web of Science ®Google Scholar
• Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003;3:685–94.
   PubMed Web of Science ®Google Scholar
• Mitelman F, Johansson B, Mertens F,. editors. Mitelman database of chromosome aberrations in cancer 2007.
   Google Scholar
• Nucci MR, Harburger D, Koontz J, Dal Cin P, Sklar J. Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms. Am J Surg Pathol 2007;31:65–70.
   PubMed Web of Science ®Google Scholar
• Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 2004;93:204–8.
   PubMed Web of Science ®Google Scholar
• Silverberg SG. Leiomyosarcoma of the uterus. A clinicopathologic study. Obstet Gynecol 1971;38:613–28.
   PubMed Web of Science ®Google Scholar
• Mark RJ, Poen J, Tran LM, Fu YS, Heaps J, Parker RG. Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies. Am J Clin Oncol 1996;19: 59–64.
   PubMed Web of Science ®Google Scholar
• Thomas DB. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives: The influence of combined oral contraceptives on risk of neoplasms in developing and developed countries. Contraception 1991;43:695–710.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002;346:1832–3.
   PubMed Web of Science ®Google Scholar
• Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, . Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002;20:2758–60.
   PubMed Web of Science ®Google Scholar
• Chu CS, Lin LL, Rubin SC. Cancer of the uterine body. DeVita, Hellman, and Rosenberg's cancer: Principles & practice of oncology. 8th ed. DeVita VT, Lawrence TS, Rosenberg SA, editors. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008. pp 1543–63.
   Google Scholar
• Nordal RR. Uterine sarcomas in Norway 1956–1992: An epidemiological and clinicopathological study. A thesis. Oslo: Faculty of Medicine – University of Oslo; 1998.
   Google Scholar
• Köhler G, Evert M. Uterine sarkome und mischtumoren. 1st ed. Berlin: De Gruyter; 2009. pp 7–120.
   Google Scholar
• Patsner B, Mann WJ. Use of serum CA-125 in monitoring patients with uterine sarcoma. A preliminary report. Cancer 1988;62:1355–8.
   PubMed Web of Science ®Google Scholar
• Brocker KA, Alt CD, Eichbaum M, Sohn C, Kauczor HU, Hallscheidt P. Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: Part 1. Strahlenther Onkol 2011;187:611–8.
   PubMed Web of Science ®Google Scholar
• Chander S, Ergun EL. Positron emission tomographic-computed tomographic imaging of a uterine sarcoma. Clin Nucl Med 2003;28:443–4.
   PubMedGoogle Scholar
• Umesaki N, Tanaka T, Miyama M, Kawamura N, Ogita S, Kawabe J, . Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: A comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001;80:372–7.
   PubMed Web of Science ®Google Scholar
• Nam JH. Surgical treatment of uterine sarcoma. Best Pract Res Clin Obstet Gynaecol 2011;25:751–60.
   PubMed Web of Science ®Google Scholar
• Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: Experience in Helsinki University Central Hospital 1990–2001. Gynecol Oncol 2008;111:74–81.
   PubMed Web of Science ®Google Scholar
• FIGO Committee on gynecologic oncology. FIGO staging for uterine sarcomas. Int J Gynecol Obstet 2009;106:277. Corrigendum to FIGO staging for uterine sarcomas. Int J Gynecol Obstet 2009;104:179.
   Google Scholar
• Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009;104:177–8.
   PubMed Web of Science ®Google Scholar
• Denschlag D, Masoud I, Stanimir G, Gilbert L. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol 2007;33:91–5.
   PubMed Web of Science ®Google Scholar
• Larson B, Silfverswärd C, Nilsson B, Pettersson F. Prognostic factors in uterine leiomyosarcoma. A clinical and histopathological study of 143 cases. The Radiumhemmet series 1936–1981. Acta Oncol 1990;29:185–91.
   PubMed Web of Science ®Google Scholar
• Nordal RN, Kjørstad KE, Stenwig AE, Tropé CG. Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976–1985. Int J Gynecol Cancer 1993;3: 110–5.
   PubMed Web of Science ®Google Scholar
• Evans HL. Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer 1982;50:2170–82.
   PubMed Web of Science ®Google Scholar
• Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, . Endometrial stromal sarcoma: A population-based analysis. Br J Cancer 2008;99:1210–5.
   PubMed Web of Science ®Google Scholar
• Bodner K, Bodner-Adler B, Obermair A, Windbichler G, Petru E, Mayerhofer S, . Prognostic parameters in endometrial stromal sarcoma: A clinicopathologic study in 31 patients. Gynecol Oncol 2001;81:160–5.
   PubMed Web of Science ®Google Scholar
• D’Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol 2009;40:1571–85.
   PubMed Web of Science ®Google Scholar
• Clement PB. Müllerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases. Am J Surg Pathol 1989;13:28–38.
   PubMed Web of Science ®Google Scholar
• Krivak TC, Seidman JD, McBroom JW, MacKoul PJ, Aye LM, Rose GS. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: Comparison of treatment and survival. Gynecol Oncol 2001;83:89–94.
   PubMed Web of Science ®Google Scholar
• Kaku T, Silverberg SG, Major FJ, Miller A, Fetter B, Brady MF. Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. Int J Gynecol Pathol 1992;11:75–88.
   PubMed Web of Science ®Google Scholar
• Fox H. Ploidy in gynaecological cancers. Histopathology 2005;46:121–9.
   PubMed Web of Science ®Google Scholar
• Kildal W, Abeler VM, Kristensen GB, Jenstad M, Thoresen SØ, Danielsen HE. The prognostic value of DNA ploidy in a total population of uterine sarcomas. Ann Oncol 2009;20: 1037–41.
   PubMed Web of Science ®Google Scholar
• Atkins KA, Arronte N, Darus CJ, Rice LW. The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol 2008;32:98–102.
   PubMed Web of Science ®Google Scholar
• Bodner-Adler B, Bodner K, Czerwenka K, Kimberger O, Leodolter S, Mayerhofer K. Expression of p16 protein in patients with uterine smooth muscle tumors: An immunohistochemical analysis. Gynecol Oncol 2005;96:62–6.
   PubMed Web of Science ®Google Scholar
• O’Neill CJ, McBride HA, Connolly LE, McCluggage WG. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 2007;50:851–8.
   PubMed Web of Science ®Google Scholar
• Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol 2008;27:326–32.
   PubMed Web of Science ®Google Scholar
• Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 2001;32:984–7.
   PubMed Web of Science ®Google Scholar
• Akhan SE, Yavuz E, Tecer A, Iyibozkurt CA, Topuz S, Tuzlali S, . The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol 2005;99: 36–42.
   PubMed Web of Science ®Google Scholar
• Swisher EM, Gown AM, Skelly M, Ek M, Tamimi HK, Cain JM, . The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol 1996;60:81–8.
   PubMed Web of Science ®Google Scholar
• Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, . ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol 2004;95:583–7.
   PubMed Web of Science ®Google Scholar
• Amant F, Schurmans K, Steenkiste E, Verbist L, Abeler VM, Tulunay G, . Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma. Gynecol Oncol 2004;93:680–5.
   PubMed Web of Science ®Google Scholar
• Perri T, Korach J, Sadetzki S, Oberman B, Fridman E, Ben-Baruch G. Uterine leiomyosarcoma: Does the primary surgical procedure matter? Int J Gynecol Cancer 2009;19: 257–60.
   PubMed Web of Science ®Google Scholar
• Della Badia C, Karini H. Endometrial stromal sarcoma diagnosed after uterine morcellation in laparoscopic supracervical hysterectomy. J Minim Invasive Gynecol 2010;17:791–3.
   PubMed Web of Science ®Google Scholar
• Einstein MH, Barakat RR, Chi DS, Sonoda Y, Alektiar KM, Hensley ML, . Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. Int J Gynecol Cancer 2008;18:1065–70.
   PubMed Web of Science ®Google Scholar
• Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, . Prognostic factors and treatment outcomes of patients with uterine sarcoma: Analysis of 127 patients at a single institution, 1989–2007. J Cancer Res Clin Oncol 2008;134:1277–87.
   PubMed Web of Science ®Google Scholar
• Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus. Ann Surg Oncol 2011;18:3453–61.
   PubMed Web of Science ®Google Scholar
• Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL Jr. Treatment of endometrial stromal tumors. Gynecol Oncol 1990;36:60–5.
   PubMed Web of Science ®Google Scholar
• Amant F, De Knijf A, Van Calster B, Leunen K, Neven P, Berteloot P, . Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer 2007;97:1194–9.
   PubMed Web of Science ®Google Scholar
• Leitao MM, Sonoda Y, Brennan MF, Barakat RR, Chi DS. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol 2003;91: 209–12.
   PubMed Web of Science ®Google Scholar
• Giuntoli RL 2nd, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, . Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003;89:460–9.
   PubMed Web of Science ®Google Scholar
• Li AJ, Giuntoli RL 2nd, Drake R, Byun SY, Rojas F, Barbuto D, . Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol 2005;106:1304–8.
   PubMed Web of Science ®Google Scholar
• Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: Emphasis on impact of lymphadenectomy and oophorectomy. Cancer 2008;112:820–30.
   PubMed Web of Science ®Google Scholar
• Shah JP, Bryant CS, Kumar S, Ali-Fehmi R, Malone JM Jr, Morris RT. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol 2008;112:1102–8.
   PubMed Web of Science ®Google Scholar
• Sutton G, Kavanagh J, Wolfson A, Tornos C. Corpus: Mesenchymal tumors. Principles and practice of gynecologic oncology, 5th ed. Barakat R, Markman M, Randall ME, editors. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009. pp 733–61.
   Google Scholar
• Tse KY, Crawford R, Ngan HY. Staging of uterine sarcomas. Best Pract Res Clin Obstet Gynaecol 2011;25:733–49.
   PubMed Web of Science ®Google Scholar
• Giuntoli RL 2nd, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol 2007;106:82–8.
   PubMed Web of Science ®Google Scholar
• Anraku M, Yokoi K, Nakagawa K, Fujisawa T, Nakajima J, Akiyama H, . Pulmonary metastases from uterine malignancies: Results of surgical resection in 133 patients. J Thorac Cardiovasc Surg 2004;127:1107–12.
   PubMed Web of Science ®Google Scholar
• McCormack PM, Martini N. The changing role of surgery for pulmonary metastases. Ann Thorac Surg 1979;28:139–45.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006;141:537–43; discussion 543–4.
   PubMed Web of Science ®Google Scholar
• Chen H, Pruitt A, Nicol TL, Gorgulu S, Choti MA. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg 1998;2:151–5.
   PubMedGoogle Scholar
• Tepetes K, Tsamandas AC, Ravazoula P, Petsas T, Bonikos DS, Karavias DD. Survival for 5 years after repeat liver resections and multimodality treatment for metastatic intestinal leiomyosarcoma: Report of a case. Surg Today 2002;32: 925–8.
   PubMed Web of Science ®Google Scholar
• Lang H, Nussbaum KT, Kaudel P, Frühauf N, Flemming P, Raab R. Hepatic metastases from leiomyosarcoma: A single-center experience with 34 liver resections during a 15-year period. Ann Surg 2000;231:500–5.
   PubMed Web of Science ®Google Scholar
• Livi L, Paiar F, Shah N, Blake P, Villanucci A, Amunni G, . Uterine sarcoma: Twenty-seven years of experience. Int J Radiat Oncol Biol Phys 2003;57:1366–73.
   PubMed Web of Science ®Google Scholar
• Knocke TH, Kucera H, Dörfler D, Pokrajac B, Pötter R. Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer 1998;83:1972–9.
   PubMed Web of Science ®Google Scholar
• Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, . Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44: 808–18.
   PubMed Web of Science ®Google Scholar
• Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos SM, . Uterine neoplasms. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009;7:498–531.
   PubMed Web of Science ®Google Scholar
• Sutton G, Blessing J, Hanjani P, Kramer P; Gynecologic Oncology Group. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 2005;96:749–52.
   PubMed Web of Science ®Google Scholar
• Currie J, Blessing JA, Muss HB, Fowler J, Berman M, Burke TW. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: A Gynecologic Oncology Group study. Gynecol Oncol 1996;61:27–30.
   PubMed Web of Science ®Google Scholar
• Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, . Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 2002;20:2824–31.
   PubMed Web of Science ®Google Scholar
• Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008;109:329–34.
   PubMed Web of Science ®Google Scholar
• Muss HB, Bundy B, DiSaia PJ, Homesley HD, Fowler WC Jr, Creasman W, . Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985;55:1648–53.
   PubMed Web of Science ®Google Scholar
• Spano JP, Soria JC, Kambouchner M, Piperno-Neuman S, Morin F, Morere JF, . Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol 2003;20:87–93.
   PubMed Web of Science ®Google Scholar
• Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience PC, Dörken B, . Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: Single center experience with 10 cases and review of the literature. Gynecol Oncol 2006;101:464–9.
   PubMed Web of Science ®Google Scholar
• Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol 2007;110:518–20.
   PubMed Web of Science ®Google Scholar
• Sutton G, Blessing JA, Park R, DiSaia PJ, Rosenshein N. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: A study of the Gynecologic Oncology Group. Obstet Gynecol 1996;87:747–50.
   PubMed Web of Science ®Google Scholar
• Scandinavian Sarcoma Group and Oncologic Center, Lund, Sweden. Recommendations for the diagnosis and treatment of intraabdominal, retroperitoneal and uterine sarcoma. December 2008. Available from: www.ssg-org.net, SSG XVII, Version 2, 1–37.
   Google Scholar
• Garg G, Shah JP, Liu JR, Bryant CS, Kumar S, Munkarah A, . Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: A population-based study. Int J Gynecol Cancer 2010;20:1201–6.
   PubMed Web of Science ®Google Scholar
• Carlson JW. Sarcomas of the uterus. Staging of gynecologic malignancies handbook. Society of Gynecologic Oncologists, 3rd edition, January 2010. pp. 41–4.
   Google Scholar